Image 1_A COP1-HY5-ABI5 module regulates ABA-mediated post-germination developmental arrest.pdf door Deeksha Singh (11009626)

Onderwerpen:

<b>The Dynamics of Sustainable Supply Chains: An Evolutionary Game of Leadership, AI Ethics, and Workforce Empowerment</b> door Rui Du (22668368)

Onderwerpen:

2D–shear-wave elastography example: non-MAFLD CKD case (male, 54 years). door Zienab M. Saad (22676502)

Onderwerpen:

2D–shear-wave elastography example: MAFLD + CKD case (male, 65 years). door Zienab M. Saad (22676502)

Onderwerpen:

eGFR in the study participants. door Zienab M. Saad (22676502)

Onderwerpen:

Demographic and Clinical Characteristics of Study Participants. door Zienab M. Saad (22676502)

Onderwerpen:

Stratification of Liver Stiffness according to eGFR in the MAFLD group. door Zienab M. Saad (22676502)

Onderwerpen:

Medication-inclusive multivariable logistic regression for MAFLD. door Zienab M. Saad (22676502)

Onderwerpen:

Receiver operating characteristic (ROC) curve analysis comparing the performance of non-invasive fibrosis scores in MAFLD patients. door Zienab M. Saad (22676502)

Onderwerpen:

Comparison of Non-invasive Liver Fibrosis Scores. door Zienab M. Saad (22676502)

Onderwerpen:

A. Violin plots showing eGFR distribution in MAFLD (red) vs. non-MAFLD (blue) groups. door Zienab M. Saad (22676502)

Onderwerpen:

Proposed pathophysiological crosstalk between MAFLD and CKD. door Zienab M. Saad (22676502)

Onderwerpen:

Liver Stiffness and Fibrosis Grading by MAFLD Status. door Zienab M. Saad (22676502)

Onderwerpen:

2D–shear-wave elastography example: MAFLD + CKD case (female, 57 years). door Zienab M. Saad (22676502)

Onderwerpen:

Grades of liver fibrosis in MAFLD group (grey) and non-MAFLD group (black). door Zienab M. Saad (22676502)

Onderwerpen:

Multivariable logistic regression models for MAFLD predictors. door Zienab M. Saad (22676502)

Onderwerpen:

Liver Fibrosis Characteristics by CKD Stage in MAFLD Patients (n = 64). door Zienab M. Saad (22676502)

Onderwerpen:

Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells door Sushil Kumar (20371917)

Onderwerpen:

Supplementary Figure 1: Activation of AD-MSCs and PSCs by Muc5ac door Sushil Kumar (20371917)

Onderwerpen:

Supplementary Figure 4: RNA-sequencing in the primary AD-MSCs, BM-MSCs, and PSCs after treatment with KC and KCM serum door Sushil Kumar (20371917)

Onderwerpen: